Prevalence and prognostic implication of stress hyperglycemia in patients of acute ST elevation myocardial infarction in a tertiary care centre in Eastern India

Authors
Biswaupark Sarkar, MD. DM¹, Sharmistha Chatterjee MD², Biswajit Majumder MD DM FACC FSCAI³

¹Assistant Professor, Department of Cardiology, R.G Kar Medical College, Kolkata, India
Email: sarkar.biswaupark13@gmail.com, Ph No. 9433113863

²Assistant Professor, Department Of Biochemistry, College Of Medicine and Sagore Datta Hospital, Kolkata, India
Email: sharmisthacmajumder@yahoo.co.in, Phone No.-9830477927

³Associate Professor, Department of Cardiology, R.G Kar Medical College, Kolkata, India

Corresponding Author
Biswaupark Majumder MD DM FACC FSCAI
181B/1 Kabi Guru Sarani Kolkata-700038, India
Email: majumderbiswaupark1972@gmail.com, Mobile-9830295168

ABSTRACT
This observational study was carried out in non-diabetic patients admitted with ST elevation MI within 24 hrs of onset of chest pain with the aim of investigating the association and prognostic implications between stress hyperglycemia and STEMI The study population comprised 58 patients, aged 30-70 years, presenting with acute ST elevated myocardial infarction (MI) within 24 hours of chest pain admitted in the Department. Patients who were admitted more than 24 hrs from the onset of symptoms, known diabetics, and those with renal failure (creatinine>1.5), inflammatory disorders, infection and malignancy were excluded. Logistic regression analysis admission sugar levels were found to be a significant predictor of MPI, WMS, WMSI, CRP.

In conclusion, an association among admission blood glucose level, left ventricular EF, WMS, WMSI, MPI, CRP and CPKMB were observed in ST elevation AMI patients in our study.

Keywords: stress hyperglycemia, acute STEMI, cardiac enzymes, inflammatory markers, prognosis, echocardiographic parameters.

Introduction
Acute myocardial infarction associated with ST elevation (STEMI) is frequently accompanied by hyperglycemia at the time of hospital admission. There is an ongoing debate as to whether this hyperglycemia is a transient elevation of blood glucose (stress hyperglycemia) as a result of acute coronary syndrome or a manifestation of latent diabetes. Recent observational studies have showed that stress hyperglycaemia is an important prognostic indicator in acute myocardial infarction (AMI)¹ and may be a reflection of the severity of
the underlying condition and not a cause of it. It is well known that while type 2 diabetics have a threefold elevated risk of major cardiovascular disease, pre-diabetics have a twofold increased risk of the same (in the absence of persistent hyperglycemia). Therefore, knowledge about the prevalence and prognostic implication of hyperglycemia in AMI patients along with other morbidity and mortality predictors may help to generate predictive models that can aid clinician decision making, in particular in identifying patients who are at high risk or low risk of death. Such risk assessment methods may help in effective utilization of health resources and in that way may reduce the economic burden of our country.

In this study, we tried to investigate the interrelationship between blood glucose level at the time of admission (henceforth referred to as admission plasma glucose or APG) and the relevant biochemical parameters in ST elevation myocardial infarction (STEMI) patients in a tertiary care centre in Eastern India. We also carried out a review of the available literature data on the prognostic implication of stress hyperglycemia in acute STEMI patients and compared it with our findings.

Aims and Objectives
The aims of the study are- to assess the prevalence of stress hyperglycaemia in patients with STEMI, to analyze the available literature data on prognostic implication of admission hyperglycaemia in patients with STEMI and to investigate the association between stress hyperglycaemia, inflammatory markers and echocardiographic parameters of functional outcome.

Materials and Methods
This observational and cross sectional study was conducted in the Department of Cardiology, R.G.Kar Medical College, Kolkata, a tertiary care centre of Cardiology from April 2014 to April 2015. The study population comprised of 58 patients, aged 30-70 years, presenting with acute ST elevated myocardial infarction (MI) within 24 hours of chest pain admitted in the Department. A written informed consent to participate in the study was taken from them. Patients who were admitted more than 24 hrs from the onset of symptoms, known diabetics, and those with renal failure (creatinine>1.5), inflammatory disorders, infection and malignancy were excluded.

STEMI was defined based on the criteria established by current guidelines as persistent (>30mins) retrosternal pain associated to ST segment elevation >0.1 mv in two or more limb leads or >0.2 mv in two or more precordial leads or acute left bundle branch block (LBBB). All relevant demographic data were obtained from all patients according to proforma. Their clinical history and physical examination were noted. Hyperglycaemia has been defined as an admission plasma glucose of >140 mg/dl (7.8 mmol/l) (11). DM has been defined as prior history of diabetes obtained from previous records or when patients report receiving pharmacologic treatment for DM or HbA1c values >6.5%.

All patients received recommended standard management for STEMI. All diabetic or non-diabetic patients with hyperglycaemia in acute phase of STEMI received subcutaneous short acting insulin according to digital glycaemic test. Measurement of brachial blood pressure, BMI, plasma glucose level, HbA1C, Troponin T, CPK MB, CRP and other routine blood tests are obtained on admission. All biochemical parameters were estimated in a clinical laboratory following quality control.
Table 1: Table showing a comparison of the relevant parameters in 2 groups of patients.

| Baseline characteristics of patients | Stress hyperglycaemia | Normoglycaemia |
|--------------------------------------|-----------------------|----------------|
| Patients (n)                         | 21                    | 18             |
| Sex (m/f)                            | 14/7                  | 12/6           |
| BMI (kg/msq)                         | 26±0.5                | 25±0.3         |
| SBP (mmHg)                           | 128±10                | 120±12         |
| DBP (mmHg)                           | 83±5                  | 80±7           |
| Mean age (yrs)                       | 63.10±5.59            | 60.11±7.36     |
| EF                                   | 39.21±6.73            | 43.05±3.79     |
| Wall Motion Score (WMS)              | 30.67±4.97            | 23.89±2.47     |
| Wall motion score index (WMSI)       | 1.788±0.364           | 1.417±0.120    |
| CPK MB (iu/ml)                       | 207.71±70.54          | 166.67±47.029  |
| CRP (mg/dl)                          | 13.05±1.8             | 10.44±1.68     |
| Admission blood glucose level (mg/dl)| 228±38.26             | 97.67±16.29    |
| Myocardial Performance Index (MPI)   | 0.6048±0.061          | 0.5222±0.484   |

Of the 58 patients, 19 (33%) patients were excluded from the study as they were categorized as diabetic as per definition followed in the study. The stress hyperglycaemia group consisted of 21 (36%) with no prior history of diabetes, who were found to have on APG >140 mg/dl and HbA1c level <6.5%. The rest 18 (31%) patients comprised the normoglycaemic group. Table 1 depicts the baseline characteristics of the study group. There were no differences in the sex distribution, smoking habits, level of plasma cholesterol and triglyceride level or creatinine level in both the groups. The mean age is little higher in stress hyperglycaemia group but it is not statistically significant (63.10±5.6 vs 60.11±7.4). Blood pressure and heart rate were slightly higher in stress hyperglycaemia group. Patients in stress hyperglycaemia group had significantly higher APG level compared to normoglycaemia group (p<0.0001). The APG in stress hyperglycaemia group was 228±38.26 mg/dl whereas it was 97.67±16.29 mg/dl in normoglycaemia group. CPK Mb level was significantly higher in stress hyperglycaemia group (207.71±70.54 vs 166.67±47.03) as compared to normoglycaemia group and it was statistically significant (p<0.001). Moreover plasma CRP levels were higher in stress hyperglycaemia group than in normoglycaemia group (p<0.043).

Echocardiographic analysis was presented in Table 1. Stress hyperglycaemia group patients had higher Wall Motion Score (WMS) (p<0.0001) and Wall Motion Score Index (WMSI) (p<0.0001), but lower Ejection Fraction (EF) (p<0.09) than normoglycaemic patients. Moreover they had an increased Myocardial Performance Index (MPI) (p<0.0001).

In logistic regression analysis admission sugar levels were found to be a significant predictor of MPI, WMS, WMSI, CRP.

**Discussion**

The prevalence of stress hyperglycaemia in our study was around 36% as against 25-50% in other studies. In our study, hyperglycaemia was associated with higher CPK MB level, infarct size, WMS and WMSI and negatively correlated with EF. The increase in MPI, which measures both systolic and diastolic parameters of ventricular function, indicates a worse functional outcome of the STEMI in stress hyperglycaemia patients. Hyperglycaemic patients had also had higher circulatory levels of CRP compared to normoglycaemics. The positive correlation that we found between blood glucose level and CRP also suggests that the increased inflammatory process may be a link between hyperglycemia and...
poor functional cardiac outcome in hyperglycemic patients during AMI. Stress hyperglycaemia represents increased blood glucose level that is result of neurohormonal process in organism exposed to stress. Increased glucose level during stress is result of sympathetic nervous system activation and raised production of catecholamines (adrenaline and noradrenaline) and cortisol that stimulate process of gluconeogenesis, glycogenolysis and lipolysis. These hormones are responsible for insulin resistance, on both receptor and post receptor level, thus leading to simultaneous hyperglycaemia, hyperinsulinemia and insulin resistance (8).

Increased APG is associated with an elevated risk of in-hospital mortality as well as long term mortality (9,10) irrespective of previous diabetic status. Hyperglycaemia may lead to fatal arrhythmias, significant QT prolongation, impaired left ventricular function, and a larger infarct size due to an increased incidence of the no-reflow phenomenon. Animal studies have demonstrated that acute hyperglycaemia may abolish ischaemic pre-conditioning. Finally, a worse myocardial performance has been demonstrated in patients with acute MI(myocardial infarction) and concomitant hyperglycaemia. The association of MI with increased thrombophilia is an old finding. It has been reported that increased platelet activation after an MI is correlated with hyperglycaemia in non-diabetic patients. The possible role of hyperglycaemia in the activation of blood coagulation has been previously reviewed. It emerges that acute glycaemic variations are accompanied with a series of alterations in coagulation that are likely to cause a thrombosis. Acute hyperglycaemia induces a shortening of the fibrinogen half-life, increases in fibrinopeptide A, fragments of pro-thrombin, factor VII, and in platelet aggregation, which are all phenomena suggesting increased activation of thrombosis.

However, our study has got certain limitations. Firstly, due to observational nature and small sample size of this study, the possibility of selection bias and/or residual confounding factors from unknown or unmeasured covariates cannot be excluded. Secondly, this is a single centre observational study, so we should be cautious in hypothesizing about the mechanism involved and the generalizability of our conclusions to other population.

**Conclusion**

Hyperglycaemia on admission is a common occurrence in patients with STEMI. It is not simply a manifestation of stress; rather it is an important prognostic indicator of functional cardiac outcome and is mainly a reflection of severity of underlying condition and not a cause of it. It can be used in risk stratification of these patients. In conclusion, an association among admission blood glucose level, left ventricular EF, WMS, WMSI, MPI, CRP and CPKMB were observed in ST elevation AMI patients in our study.

**References**

1. Capes SE, Hunt D, Malmberg K. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355(9206):773–778. Google Scholar CrossRef Medline

2. A. Dirkali, Tj. van der Ploeg M. Nangrahary J.H. Cornel. The impact of admission plasma glucose on long-term mortality after STEMI and NSTEMI myocardial infarction. International journal of cardiology. October 1, 2007Volume 121, Issue 2, Pages 215–217

3. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek EP, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized
diabetes. Circulation. 2005;111(23):3078–3086. [PubMed]
4. Meier JJ, Deifuss S, Klamann A, Launhardt V, Schmiegel WH, Nauck MA. Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA) Diabetes Care. 2005;28(10):2551–2553. [PubMed]
5. Nordin C, Amiruddin R, Rucker L, Choi J, Kohli A, Marantz PR. Diabetes and stress hyperglycemia associated with myocardial infarctions at an urban municipal hospital: prevalence and effect on mortality. Cardiol Rev. 2005;13(5):223–230. [PubMed]
6. Gokhroo R, Mittal SR. Electrocardiographic correlates of hyperglycemia in acute myocardial infarction. Int J Cardiol 1989;22:267–269.
7. Hiesmayr M. Hyperglycaemia and outcome after myocardial infarction and cardiac surgery: So what? Semin Cardiothorasic Vasc Anesth 2006; 10:220-3.
8. H. Wei Christina , Litwin Sheldon E. Hyperglycemia and Adverse Outcomes in Acute Coronary Syndromes: Is Serum Glucose the Provocateur or Innocent Bystander? Diabetes Volume 63, July 2014
9. Wahab N, Cowden E, Pearce N, et al. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol 2002; 40: 1748-54.
10. Wong V, Ross D, Park D, et al. Hyperglycaemia: still an important predictor of adverse outcomes following AMI in reperfusion era. Diabetes Res Clin Pract 2004; 64: 85-91.
11. Marfella R, Nappo F, De Angelis L et al. The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia 2000; 43:571–575.
12. Ishihara M, Inoue I, Kawagoe T et al. Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction. Am Heart J 2003; 146:674–678.
13. Iwakura K, Ito H, Ikushima M, Kawano S et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003;41:1–7.
14. Kersten JR, Schmeling TJ, Orth KG et al. Acute hyperglycemia abolishes ischemic preconditioning in vivo. Am J Physiol 1998 ;275:H721–H725.
15. Poulsen SH, Jensen SE, Tei C et al. Value of the Doppler index of myocardial performance in the early phase of acute myocardial infarction. J Am Soc Echocardiogr 2000;13:723–730.
16. Baele G, Mussche M, Vermeire P. Serum fibrin-fibrinogen products in acute myocardial infarction. Lancet 1972;1:689–690.
17. Chandler AB, Chapman I, Erhardt LR et al. Coronary thrombosis in myocardial infarction. Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. Am J Cardiol 1974;34:823–833.
18. Oswald GA, Smith CC, Delamothe AP et al. Raised concentrations of glucose and adrenaline and increased in vivo platelet activation after myocardial infarction. Br Heart J 1988;59:663–671.
19. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993;36:1119–1125.
20. Jones RL, Peterson CM. Reduced fibrinogen survival in diabetes mellitus a
reversible phenomenon. J Clin Invest 1979;63:485–493.

21. Ceriello A, Giugliano D, Quatraro A et al. Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. Metabolism 1989;38:1162–1163.

22. Ceriello A, Giacomello R, Stel G et al. Hyperglycemia-induced thrombin formation in diabetes. The possible role of the oxidative stress. Diabetes 1995;44:924–928.